Kato Ikuma, Yoshida Akihiko, Ikegami Masachika, Okuma Tomotake, Tonooka Akiko, Horiguchi Shinichiro, Funata Nobuaki, Kawai Akira, Goto Takahiro, Hishima Tsunekazu, Aoki Ichiro, Motoi Toru
Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Department of Molecular Pathology, Yokohama City University School of Medicine, Yokohama, Japan.
Histopathology. 2016 Dec;69(6):1012-1020. doi: 10.1111/his.13042. Epub 2016 Sep 27.
Although desmoplastic fibroblastoma (DFB) and fibroma of tendon sheath (FTS) are well-established entities, they may show overlapping clinicopathological features. In addition, cytogenetic data showing a shared 11q12 rearrangement in a small number of cases suggest a close link between these entities. A recent microarray study revealed up-regulation of FOSL1 mRNA in DFBs with 11q12 rearrangement. The aim of this study was to clarify the relationship between DFB and FTS.
We tested 42 cases diagnosed originally as either DFBs or FTSs for interobserver concordance based on the existing histological criteria and correlated the diagnosis with FOSL1 immunohistochemistry. In addition, FOSL1 gene status was determined by chromogenic in-situ hybridization (CISH). Using joint histological evaluation, 41 of 42 tumours were classified unanimously by three pathologists into 25 DFBs and 16 FTSs, whereas only one case received discordant opinions. Immunohistochemically, all DFBs showed diffuse, strong FOSL1 nuclear immunoreactivity (25 of 25, 100%), while none of the FTSs showed such overexpression. None of the selected 42 DFB mimics overexpressed FOSL1. FOSL1 was not rearranged in seven DFBs tested by CISH.
We confirm here that DFB and FTS are two distinct entities that can be distinguished using the existing histological criteria. This distinction corresponds perfectly with FOSL1 immunohistochemical expression status, and diffuse strong FOSL1 expression specific to DFBs sharpens the border between the two categories. FOSL1 overexpression in DFB may not be caused directly by FOSL1 gene rearrangement. FOSL1 may also be a diagnostic aid for differentiating DFB from other histological mimics.
尽管促纤维组织增生性纤维母细胞瘤(DFB)和腱鞘纤维瘤(FTS)是已明确的实体瘤,但它们可能具有重叠的临床病理特征。此外,少数病例的细胞遗传学数据显示存在共同的11q12重排,提示这些实体瘤之间存在密切联系。最近一项微阵列研究显示,11q12重排的DFB中FOSL1 mRNA上调。本研究的目的是阐明DFB与FTS之间的关系。
我们根据现有的组织学标准,对42例最初诊断为DFB或FTS的病例进行了观察者间一致性测试,并将诊断结果与FOSL1免疫组化结果相关联。此外,通过显色原位杂交(CISH)确定FOSL1基因状态。通过联合组织学评估,42个肿瘤中的41个被三位病理学家一致分类为25个DFB和16个FTS,而只有1例存在不同意见。免疫组化方面,所有DFB均显示弥漫性、强FOSL1核免疫反应性(25/25,100%),而FTS均未显示这种过表达。所选的42例DFB模仿物均未过表达FOSL1。通过CISH检测,7个DFB中FOSL1未发生重排。
我们在此证实,DFB和FTS是两个不同的实体瘤,可使用现有的组织学标准进行区分。这种区分与FOSL1免疫组化表达状态完全相符,DFB特有的弥漫性强FOSL1表达明确了两类肿瘤的界限。DFB中FOSL1过表达可能不是由FOSL1基因重排直接引起的。FOSL1也可能有助于将DFB与其他组织学模仿物区分开来。